{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-047087","form_type":"8-K","ticker":"JAZZ","cik":"0001232524","company_name":"Jazz Pharmaceuticals plc","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.614213+00:00","generated_at":"2026-06-05T10:47:12.777213+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Jazz Pharmaceuticals appoints Patrick Kennedy to Board; Peter Gray not standing for re-election","bullets":["Patrick Kennedy appointed as Class I director effective March 1, 2024; term expires at 2024 AGM.","Kennedy will serve on the Audit Committee; receives standard non-employee director compensation.","Peter Gray notified the Board he will not stand for re-election at the 2024 Annual Meeting, with no disagreement with the Company.","Kennedy entered into Jazz's standard indemnification agreement for directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-047087","json":"https://secwatch.observer/filing/0001193125-24-047087.json","markdown":"https://secwatch.observer/filing/0001193125-24-047087.md","text":"https://secwatch.observer/filing/0001193125-24-047087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1232524/000119312524047087/0001193125-24-047087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1232524/000119312524047087/d783837d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T10:47:12.777213+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"187d8bee8f","claim":"Peter Gray resigned as Director at Jazz Pharmaceuticals plc.","evidence_excerpt":"Peter Gray notified the Board that he will not stand for re-election to the Board, when his term expires, at the 2024 Annual Meeting.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1232524/000119312524047087/0001193125-24-047087-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ee66a9367c","claim":"Patrick Kennedy was appointed as Director at Jazz Pharmaceuticals plc.","evidence_excerpt":"appointed Patrick Kennedy to the Board, effective as of March 1, 2024, as a Class I director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1232524/000119312524047087/0001193125-24-047087-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}